Why Eli Lilly (LLY) rose 5.58%
Eli Lilly (LLY) rose 5.58% on October 29, 2026 — Raised outlook and Zepbound growth lift Lilly.
What happened
Healthcare & Biotech rallied about 5.4% at the median across the group, and Eli Lilly rose 5.6% within that move.
Why it moved
Most of the move came from the group rally, which lifted peers by a similar amount and points to shared sector flows.
Why it matters
Lilly is the anchor of the GLP-1 leg within Healthcare & Biotech, so its guidance raises are a read on whether obesity-drug demand is still accelerating. That demand story is what has kept the sector's leaders bid.
What would break the thesis
The thesis weakens if Zepbound prescription growth slows or management trims the raised outlook later. Watch weekly script data and the next guidance update for signs the acceleration is fading.